Overview

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Status:
Recruiting
Trial end date:
2027-04-21
Target enrollment:
Participant gender:
Summary
This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard therapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bayer